CN110627912A

CN110627912A - Bionic fiber network antibody self-assembly material and preparation method and application thereof

Info

Publication number: CN110627912A
Application number: CN201910995134.4A
Authority: CN
Inventors: 王磊; 王浩
Original assignee: National Center for Nanosccience and Technology China
Current assignee: Zhongke guona Kangda (Beijing) Biotechnology Co.,Ltd.
Priority date: 2019-10-18
Filing date: 2019-10-18
Publication date: 2019-12-31
Anticipated expiration: 2039-10-18
Also published as: CN110627912B

Abstract

The invention relates to a bionic fiber network antibody self-assembly material, a preparation method and application thereof, wherein the bionic fiber network antibody self-assembly material comprises a targeting unit, a fiber unit and a hydrophobic unit which are sequentially connected through amido bonds, and the chemical structure of the bionic fiber network antibody self-assembly material is R₁‑R₂‑R₃(ii) a Wherein R is₂From fibrous peptides having multiple hydrogen bonds within the molecule; r₃Derived from a tumor targeting peptide. The self-assembly material of the inventionThe bionic extracellular matrix forming process utilizes the combination of the nano-polypeptide and receptor protein on the surface of tumor cells to form a fiber network structure, regulates and controls the aggregation of membrane protein, and can realize the combination of multivalent bonds as a fiber network polypeptide antibody, the targeting combination capability is obviously enhanced, and the effect of the fiber network antibody is more durable. Meanwhile, the fiber network antibody does not enter cells, so that desensitization drug resistance is avoided.

Description

Bionic fiber network antibody self-assembly material and preparation method and application thereof

Technical Field

The invention relates to the field of biomedicine, in particular to a self-assembly material and a preparation method and application thereof, and particularly relates to a bionic fiber network antibody self-assembly material and a preparation method and application thereof.

Background

Tumor refers to a new organism formed by local tissue cell proliferation under the action of various carcinogenic factors, because the new organism mostly presents space occupying block-shaped protrusion, also called as neoplasm. The serious harm to the health of people caused by tumors, and the high death rate of the tumors mainly causes the rapid growth, the rapid metastasis and the strong invasion capacity of the tumors. Tumor metastasis or invasion is an extremely complex process in which tumor metastasis can be inhibited by inhibiting the activity of metallomatrix proteases, which degrade the extracellular matrix as a major factor leading to tumor metastasis, but this approach has little effect. Meanwhile, in recent years, the rapid development of nano materials leads the nano materials to be widely regarded, with the continuous deepening of nano technology in the years, the characteristics of nano substances are continuously discovered, the application field is also deepened, and the polypeptide self-assembly nano materials have good biocompatibility and mechanical property and are widely applied to biological imaging and treatment.

CN107049991A discloses a novel mesoporous silica nano drug delivery system for inhibiting tumor cell migration and invasion in a dual-targeting manner and a preparation method thereof, wherein the mesoporous silica nano drug delivery system takes a cyclic pentapeptide-hyaluronic acid as a targeting material, adriamycin as a model drug and mesoporous silica as a drug carrier. The drug delivery system can improve the inhibition rate of tumor cell migration and invasion; the preparation process is simple and has wide application prospect.

CN109091678A discloses a preparation method and application of a supermolecule assembly for inhibiting tumor invasion and diffusion, wherein a building unit takes hyaluronic acid modified by beta-cyclodextrin as a main body and magnetic nanoparticles modified by octapeptide as an object, and a nano supermolecule fiber aggregate is built through the interaction of the supermolecule main body and the object. The supermolecule assembly is directionally aggregated under the induction of a geomagnetic field or a weak magnetic field, and can be subjected to light control induction to aggregate the supermolecule assembly; the assembly can also specifically attract cancer cells in a nanofiber reticular structure, and can damage mitochondria, so that the assembly has wide application prospect in the field of tumor treatment, especially in the aspect of actively inhibiting the invasion and diffusion of tumor cells.

In summary, the prior art has few strategies for inhibiting tumor metastasis and invasion, and therefore, it is very meaningful to develop a novel therapeutic strategy with significant efficacy, which can inhibit tumor growth, metastasis and invasion.

Disclosure of Invention

Aiming at the defects of the prior art, the invention aims to provide a self-assembly material and a preparation method and application thereof, and particularly provides a bionic fiber network antibody self-assembly material and a preparation method and application thereof.

In order to achieve the purpose, the invention adopts the following technical scheme:

in a first aspect, the invention provides a bionic fiber network antibody self-assembly material, which comprises targeting units R sequentially connected through amido bonds₃Fiber unit R₂And a hydrophobic unit R₁The three units are connected through amide bonds, and the chemical structure of the three units is shown as the formula (I):

R₁-R₂-R₃formula (I);

wherein R is₂From fibrous peptides having multiple hydrogen bonds within the molecule; r₃Derived from a tumor targeting peptide.

Compared with the prior antibody technology, the invention provides a new idea and a new method of a novel bionic antibody, the fiber peptide in the self-assembly material has good biocompatibility and self-assembly capability, and the bionic extracellular matrix forming process utilizes the combination of the nano-polypeptide and receptor protein on the surface of tumor cells to form a fiber network structure, regulates and controls the aggregation of membrane protein, and the fiber network polypeptide antibody can be used as a fiber network polypeptide antibody to realize the combination of multivalent bonds. More importantly, compared with the desensitization effect and possible drug resistance generated by the traditional antibody combining endocytosis, the fiber network antibody does not enter cells, and the occurrence of desensitization drug resistance is avoided. Therefore, the nano-polypeptide bionic fiber network antibody has a great prospect in application to tumor resistance, can efficiently inhibit the growth, invasion and metastasis of tumors, and has a wide application prospect.

The tumor targeting peptide in the self-assembly material can realize active targeting on a tumor part, and improve the biological safety and bioavailability of the material.

Preferably, said R is₁The chemical structure of (a) is selected from any one of the following structures:

wherein n1, n2 and n3 are respectively and independently selected from any integer of 1-18 (such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18); the dotted line represents the attachment site. n1, n2 and n3 represent the number of carbon atoms in an alkyl chain.

From the above, in the present invention, the hydrophobic material Carboxy and R in (1)₂The amino groups of the first amino acid in the polypeptide sequence are connected through amido bond, R₂Carboxyl and R of terminal amino acid in polypeptide sequence₃The amino groups of the first amino acids in the polypeptide sequence are connected through amido bonds.

Preferably, said R is₂Any one of the following polypeptide sequences:

Lys-Leu-Val-Phe-Phe；Leu-Pro-Phe-Phe-Asp；Phe-Thr-ILe-Ser-Asp；Ile-Thr-Ser-Val-Val；Tyr-Phe-Thr-Glu-Phe；Ile-Ser-Asp-Asn-Leu；Leu-Asp-Phe-Pro-Ile；Phe-Ala-Gly-Phe-Thr；Phe-Gly-Phe-Asp-Pro；Phe-Phe-Val-Asp-Phe。

the structural formulas of the polypeptide sequences are respectively shown as follows:

Lys-Leu-Val-Phe-Phe

Leu-Pro-Phe-Phe-Asp

Phe-Thr-ILe-Ser-Asp

Ile-Thr-Ser-Val-Val

Tyr-Phe-Thr-Glu-Phe

Ile-Ser-Asp-Asn-Leu

Leu-Asp-Phe-Pro-Ile

Phe-Ala-Gly-Phe-Thr

Phe-Gly-Phe-Asp-Pro

Phe-Phe-Val-Asp-Phe

preferably, said R is₃Any one of the following polypeptide sequences:

Asp-Gly-Arg；Cys-Arg-Glu-Lys-Ala；Gly-Arg-Gly-Asp-Thr-Pro；Cys-Arg-Lys-Asp-Lys-Cys；Tyr-Cys-Asp-Gly-Phe-Tyr-Ala-Cys-Tyr-Met-Asp-Val；Val-Asn-Thr-Ala-Asn-Ser-Thr；Ala-His-Lys-His-Val-His-His-Val-Pro-Val-Arg-Leu；Cys-Gly-Lys-Gly-Gly-Met-Ser-Thr-Met-Ser-Gly。

Asp-Gly-Arg

Cys-Arg-Glu-Lys-Ala

Gly-Arg-Gly-Asp-Thr-Pro

Cys-Arg-Lys-Asp-Lys-Cys

Tyr-Cys-Asp-Gly-Phe-Tyr-Ala-Cys-Tyr-Met-Asp-Val

Val-Asn-Thr-Ala-Asn-Ser-Thr

Ala-His-Lys-His-Val-His-His-Val-Pro-Val-Arg-Leu

Cys-Gly-Lys-Gly-Gly-Met-Ser-Thr-Met-Ser-Gly

as a preferred technical scheme, the chemical structural general formula of the bionic fiber network antibody self-assembly material is R₁-R₂-R₃Wherein said R is₁Has a chemical structure ofThe dotted line represents the attachment site, said R₂Derived from the polypeptide sequence Phe-Phe-Val-Asp-Phe, said R₃Is derived from the polypeptide sequence Asp-Gly-Arg.

As a second preferred scheme of the invention, the chemical structural general formula of the bionic fiber network antibody self-assembly material is R₁-R₂-R₃Wherein said R is₂Derived from the polypeptide sequence Lys-Leu-Val-Phe-Phe, said R₃Derived from the polypeptide sequence Tyr-Cys-Asp-Gly-Phe-Tyr-Ala-Cys-Tyr-Met-Asp-Val, said R₁Has a chemical structure ofThe dotted line indicates the attachment site.

As a third preferred scheme of the invention, the general chemical structure formula of the bionic fiber network antibody self-assembly material is R₁-R₂-R₃Wherein said R is₂Derived from the polypeptide sequence Phe-Phe-Val-Asp-Phe, said R₃Derived from the polypeptide sequence Tyr-Cys-Asp-Gly-Phe-Tyr-Ala-Cys-Tyr-Met-Asp-Val, said R₁Has a chemical structure ofThe dotted line represents the connection bitAnd (4) point.

As a fourth preferred scheme of the invention, the general chemical structure formula of the bionic fiber network antibody self-assembly material is R₁-R₂-R₃Wherein said R is₂Derived from the polypeptide sequence Ile-Ser-Asp-Asn-Leu, said R₃From the polypeptide sequence Asp-Gly-Arg, said R₁Has a chemical structure ofThe dotted line indicates the attachment site.

On the other hand, the invention provides a preparation method of the bionic fiber network antibody self-assembly material, which comprises the following steps:

the bionic fiber network antibody self-assembly material is synthesized by taking amino acid with protected terminal amino group and side chain amino group and hydrophobic material as raw materials through a solid phase synthesis method.

The preparation method of the bionic fiber network antibody self-assembly material provided by the invention is synthesized according to a standard polypeptide solid phase synthesis method (SPPS). For example, the following steps can be followed:

(1) swelling the carrier resin;

(2) adopting amino acid with Fmoc protection obtained from terminal amino group, Boc protection obtained from side chain amino group and hydrophobic material as raw materials, firstly, according to R₃Amino acid sequence of (1), R₃Adding a first amino acid to the carrier resin, and performing coupling reaction and connection with the carrier resin; removing R₃Fmoc protecting group on the first amino acid, reacting R₃A second amino acid with R₃The first amino acid is coupled and ligated; until R is completed₃Condensation of all amino acids in (1);

(3) removing R₃Fmoc protecting group of the last amino acid, according to R₂Amino acid sequence of (1), R₂First amino acid with R₃The last amino acid is subjected to coupling reaction and ligation; removing R₂Fmoc protecting group on the first amino acid, reacting R₂A second amino acid with R₂The first amino acid is subjected to coupling reactionConnecting; until R is completed₂Condensation of all amino acids in (1);

(4) removing R₂Fmoc protecting group of the last amino acid, the carboxyl end of the hydrophobic molecule and R₂The last amino acid is subjected to coupling reaction and ligation;

(5) and (4) removing the product obtained in the step (4) from the carrier resin to obtain the bionic fiber network antibody self-assembly material.

In another aspect, the invention provides an application of the bionic fiber network antibody self-assembly material in preparing a medicament for inhibiting tumor growth, metastasis or invasion.

Compared with the prior art, the invention has the following beneficial effects:

Drawings

FIG. 1 is a graph of the results of mass spectrometry characterization of the self-assembled material prepared in example 1;

FIG. 2 is a transmission electron micrograph of the self-assembled nanoparticles prepared in example 2;

FIG. 3 is a transmission electron micrograph of the nanofiber prepared in example 2;

FIG. 4 is a confocal image of laser light after co-incubation of MDA-MB-231 cells with self-assembly material;

FIG. 5 is a scanning electron micrograph of the cell model MDA-MB-231 of example 4;

FIG. 6 is a graph showing the results of wound healing in example 5 using MDA-MB-231 as a cell model (a is a control group, b is an experimental group);

FIG. 7 is a graph showing the results of cell migration using MDA-MB-231 as a cell model in example 6 (a is a control group, b is an experimental group);

FIG. 8 is a graph showing the tumor growth inhibition of the mice in example 7;

FIG. 9 is a photograph of in vivo fluorescence images of mice obtained in example 7;

FIG. 10 is a graph of the results of mass spectrometry characterization of the self-assembled material prepared in example 8;

FIG. 11 is a transmission electron micrograph of self-assembled nanoparticles prepared in example 9;

FIG. 12 is a transmission electron micrograph of the nanofiber prepared in example 9;

FIG. 13 is a confocal image of laser light after co-incubation of SKBR-3 cells with self-assembly material;

FIG. 14 is a scanning electron micrograph of SKBR-3 as a cell model in example 13;

FIG. 15 is a graph showing the tumor growth inhibition curves of the mice in example 14;

FIG. 16 is a graph of survival of mice in example 14;

FIG. 17 is a graph of the results of mass spectrometry characterization of the self-assembled material prepared in example 15;

FIG. 18 is a transmission electron micrograph of self-assembled nanoparticles prepared in example 15;

FIG. 19 is a transmission electron micrograph of a nanofiber prepared in example 15;

FIG. 20 is a graph of the results of mass spectrometry characterization of the self-assembled material prepared in example 17;

FIG. 21 is a TEM image of the self-assembled nanoparticles prepared in example 17;

FIG. 22 is a TEM image of the nanofiber prepared in example 17.

Detailed Description

The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.

Example 1

In this embodiment, a bionic fiber network antibody self-assembly material is constructed, and the chemical structure of the bionic fiber network antibody self-assembly material is as follows:

namely, it is

The preparation method is synthesized according to a standard polypeptide solid phase synthesis method (SPPS).

The prepared self-assembly material is characterized by mass spectrum, and the mass spectrum characterization result is shown in figure 1, and can be known from figure 1: the main peak of the mass spectrogram can be seen to be consistent with the molecular weight of the synthesized polypeptide material, so that the synthesis of a target molecule is deduced, and the synthesis of the self-assembly material with the structure of the formula is shown to be successful.

Example 2

This example prepares a self-assembled nanoparticle solution and nanofiber dispersion of the product of example 1 by the following specific methods:

the self-assembly material prepared in example 1 was dissolved in DMSO solvent (concentration of self-assembly material was 3X 10)^-3M), get 10 μ L above-mentioned solution and place in the centrifuging tube, again slowly add 990 μ L deionized water in the centrifuging tube, prepare out the mixed solution of water content 98%, characterize the self-assembling nanoparticle who obtains with transmission electron microscope self-assembling material monomer solution (water content 98%), the result is as shown in figure 2, can see by figure 2: the self-assembled material prepared in example 1 formed self-assembled particles in an aqueous solution.

Adding anhydrous CaCl into the self-assembly nano-particle solution obtained above₂Solution of Ca²⁺The concentration is 3X 10^-5M, standing for 48 hoursObtaining the nano-fiber dispersion liquid. The obtained nanofibers were characterized by transmission electron microscopy, and the results are shown in fig. 3, which shows that: the self-assembled polypeptide material becomes short fiber-like.

Example 3

Laser confocal test:

in the embodiment, the human breast cancer cell MDA-MB-231 is taken as a cell model and cultured in a DMEM medium containing 10 percent fetal bovine serum, 100U/mL penicillin and 100 mu g/mL streptomycin at the temperature of 37.0 ℃ and CO₂The concentration of (2) was 5.0%. When the cells are cultured to logarithmic phase and the state of the cells is good, the dispersed cells are digested with trypsin for 3min, centrifuged at 1000r/min for 3min, and the supernatant is discarded. Will contain 10 per ml⁴The cell suspension of each cell was added to a confocal laser-induced cell dish, cultured for 24 hours, and then cultured in 1mL of a medium (3.0X 10) containing the self-assembly material prepared in example 1^-5M) replacing the original culture solution, putting the original culture solution into a cell culture box for culturing for 2h, pouring out the supernatant, washing the supernatant for three times by PBS, adding a proper amount of PBS, and performing a single photon laser confocal imaging test. The test results are shown in fig. 4, and it can be seen from fig. 4 that: the strong green fluorescence appears on the surface of the cancer cell, which indicates that the self-assembly material can actively target the tumor cell.

Example 4

And (3) scanning electron microscope test:

in the embodiment, human breast cancer MDA-MB-231 is taken as a cell model. The silicon wafer was placed on the bottom of the dish, and the control cells were cultured in DMEM medium containing 10% fetal bovine serum, 100U/mL penicillin and 100. mu.g/mL streptomycin for 24 hours, and the experimental cells were cultured in DMEM medium containing 10% fetal bovine serum, 100U/mL penicillin and 100. mu.g/mL streptomycin for 24 hours, followed by 1mL of the medium containing the self-assembly material prepared in example 1 (3.0X 10^-5M) replacing the original culture solution, and culturing in a cell culture box at 37.0 deg.C and CO for 2 hr₂Was 5.0%, cells were grown on the silicon wafer.

The medium was then discarded, washed three times with PBS, fixed for 2h by adding 20% glutaraldehyde solution (glutaraldehyde: PBS buffer 1:4v/v), washed two times with PBS, then the cells were dehydrated in a gradient with 30%, 50%, 70%, 90%, 100% ethanol/PBS solution, twice for each concentration, 10min each time, and finally rinsed for 30min with tert-butanol. And (4) after the treatment, putting the cells into a vacuum drying oven for drying, and observing and scanning by using a scanning electron microscope after the drying is finished. The test results are shown in fig. 5, from which it can be seen that: the surface of the tumor cells had very fine fibers formed, which demonstrates that the self-assembling material of the present invention forms fibers on the surface of the tumor cells.

Example 5

Cell wound healing assay:

in the embodiment, the human breast cancer cell MDA-MB-231 is taken as a cell model and is divided into a control group and an experimental group. Cells were seeded into 24-well cell culture plates at a concentration of 10 per ml⁴The individual cells, MDA-MB-231 cells, were cultured in DMEM medium for 24h without changing the medium, and a new 200. mu.L tip was gently scratched between the cells of the monolayer, the scratch crossing the hole, and the tip was perpendicular to the bottom of the well plate. After scratching, the well plate was gently washed 2 times with a culture medium to remove exfoliated cells, and then a fresh culture medium was added to each well, and 3.0X 10 was further added to the culture medium of the experimental group compared to the control group^-5M the self-assembled material prepared in example 1, cells were cultured for 24h, washed 2 times with PBS, fixed with absolute methanol for 30min, stained with 0.1% crystal violet (dissolved in 2% ethanol) for 30min, washed 3 times with PBS, and observed by taking pictures with a microscope.

The test results are shown in fig. 6 (a is the control group, b is the experimental group), from which it can be seen that: the blank area in the middle of the experimental group is narrower than the control group, indicating that the wound healing ability of the experimental group is strong.

Example 6

Cell migration assay:

in the embodiment, the human breast cancer cell MDA-MB-231 is taken as a cell model and is divided into a control group and an experimental group. Placing Transwell chamber without artificial matrigel into 24-well plate, removing serum from cultured MDA-MB-231 cells, starving for 12 hr, removing serum, digesting MDA-MB-231 cells with pancreatin to prepare cell suspension, and culturing with culture mediumThe cell suspension was adjusted to 5X 10 cells per ml with nutrient⁵The cells were plated out at 200. mu.L into a Transwell chamber and 3.0X 10 in the upper chamber^-5M self-assembly material prepared in example 1, cells were cultured for 24 hours by adding 500. mu.L of a medium containing 10% fetal bovine serum to the lower chamber, the chamber was taken out, the cells on the upper surface of the chamber were gently scraped off with a cotton swab, the cells on the lower surface of the chamber were fixed with absolute methanol for 30min, stained with 0.1% crystal violet (dissolved in 2% ethanol) for 30min, washed 3 times with PBS, and observed by photographing with a microscope.

The results are shown in FIG. 7 (a is the control group, b is the experimental group), from which it can be seen that: the number of cells in the experimental group is obviously reduced compared with that in the control group, and the fact that the self-assembly material can effectively inhibit the migration of tumor cells is proved.

Example 7

Animal experiments:

the experiment meets the ethical requirements of national animals, 20 Balb/c female nude mice are selected as experimental animals, the experimental animals are randomly divided into a control group and an experimental group, each group comprises 10 animals, the experimental animals are pre-fed for 7 days, and about 5 multiplied by 10 animals are inoculated to mammary gland parts of 20 mice⁶MDA-MA-231 cells, establishing mouse tumor model. When the tumor volume of the mouse is about 100mm³On the left and right, the administration treatment is started. The results of the experiment group mice administered with 200 μ L of the self-assembly material prepared in example 1 every 72 hours, the drug solution was dissolved in normal saline, the concentration was 100 μ M, the total administration was 7 times, the control group mice administered with 200 μ L of normal saline every 72 hours, the administration was 7 times, and the size of the tumor volume was observed, as shown in fig. 8 (V0 represents the tumor volume at the time of starting the administration treatment, V represents the tumor volume on days 2, 4, 6, 8, 10, 12, and 14), as can be seen from the figure: the self-assembly material can obviously inhibit the growth of tumors.

The imaging test of the small animal is carried out 72h after the first administration, and the wave band 550-600nm is collected. The results are shown in FIG. 9, from which it can be seen that: the self-assembly material has strong active targeting property.

Example 8

The prepared self-assembly material is characterized by mass spectrum, and the mass spectrum characterization result is shown in fig. 10, and can be known from fig. 10: the main peak of the mass spectrogram can be seen to be consistent with the molecular weight of the synthesized polypeptide material, so that the synthesis of a target molecule is deduced, and the synthesis of the self-assembly material with the structure of the formula is shown to be successful.

Example 11

This example prepares the self-assembled nanoparticle solution and nanofiber dispersion of the product of example 8 by the following specific methods:

the self-assembly material prepared in example 8 was dissolved in DMSO solvent (concentration of self-assembly material was 3X 10)^-3M), get 10 μ L above-mentioned solution and put into the centrifuging tube, again slowly add 990 μ L deionized water into the centrifuging tube, prepare out the mixed solution of water content 98%, characterize the self-assembling nanoparticle who obtains with transmission electron microscope self-assembling material monomer solution (water content 98%), the result is as shown in FIG. 11, can see by FIG. 11: the self-assembled material prepared in example 8 formed self-assembled particles in an aqueous solution.

Adding Her2 protein into the self-assembly nanoparticle solution obtained in the above step, wherein the concentration of Her2 protein is 3 x 10 after complete dissolution^-8And M, standing for 48 hours to obtain the nanofiber dispersion liquid. The obtained nanofibers were characterized by transmission electron microscopy, and the results are shown in fig. 12, which shows that: the self-assembled polypeptide material becomes short fiber-like.

Example 12

Laser confocal test:

in the embodiment, human breast cancer SKBR-3 is taken as a cell model and cultured in DMEM medium containing 10 percent fetal bovine serum, 100U/mL penicillin and 100 mu g/mL streptomycin at the culture temperature of 37.0 ℃ and CO₂The concentration of (2) was 5.0%. When the cells are cultured to logarithmic phase and the state of the cells is good, the dispersed cells are digested with trypsin for 3min, centrifuged at 1000r/min for 3min, and the supernatant is discarded. Will contain 10 per ml⁴The cell suspension of each cell was added to a confocal laser-induced cell dish, cultured for 24 hours, and then cultured in 1mL of a medium (3.0X 10) containing the self-assembly material prepared in example 8^-5M) replacing the original culture solution, putting the original culture solution into a cell culture box for culturing for 2h, pouring out the supernatant, washing the supernatant for three times by PBS, adding a proper amount of PBS, and performing a single photon laser confocal imaging test. The test results are shown in fig. 13, and it can be seen from fig. 13 that: the strong green fluorescence appears on the surface of the cancer cell, which indicates that the self-assembly material can actively target the tumor cell.

Example 13

And (3) scanning electron microscope test:

in the embodiment, human breast cancer SKBR-3 is used as a cell model. The silicon wafer was placed on the bottom of the dish, and the control cells were cultured in DMEM medium containing 10% fetal bovine serum, 100U/mL penicillin and 100. mu.g/mL streptomycin for 24 hours, and the experimental cells were cultured in DMEM medium containing 10% fetal bovine serum, 100U/mL penicillin and 100. mu.g/mL streptomycin for 24 hours, followed by 1mL of the medium containing the self-assembly material prepared in example 8 (3.0X 10^-5M) replacing the original culture solution, and culturing in a cell culture box at 37.0 deg.C and CO for 2 hr₂Was 5.0% and the cells were grown on silicon wafers, the subsequent steps refer to example 4.

The test results are shown in fig. 14, from which it can be seen that: the surface of the tumor cells had fibrogenesis, which demonstrates that the self-assembled material of the present invention forms fibers on the surface of the tumor cells.

Example 14

Animal experiments:

the experiment meets the ethical requirements of national animals, 20 Balb/c female nude mice are selected as experimental animals, the experimental animals are randomly divided into a control group and an experimental group, each group comprises 10 animals, the experimental animals are pre-fed for 7 days, and about 5 multiplied by 10 animals are inoculated to mammary gland parts of 20 mice⁶Establishing a mouse tumor model by using the SKBR-3 humanized breast cancer cells. Tumor body of mouseProduct is about 100mm³On the left and right, the administration treatment is started. The results of the observation of the size of the tumor volume in the experimental mice administered with 200. mu.L of physiological saline at intervals of 72 hours and 7 times of administration of the self-assembly material prepared in example 8 in physiological saline at a concentration of 100. mu.M in total, and the control mice administered with 200. mu.L of physiological saline at intervals of 72 hours are shown in FIG. 15 (V0 represents the tumor volume at the start of the administration treatment, and V represents the tumor volume at days 2, 4, 6, 8, 10, 12, and 14), as can be seen from the following graphs: the self-assembly material can obviously inhibit the growth of tumors.

And a survival curve is drawn to observe the survival rate of the mouse, and the result is shown in figure 16, and the following can be seen in the figure: the self-assembly material can obviously improve the survival rate of mice.

Example 15

The prepared self-assembly material is characterized by mass spectrum, and the mass spectrum characterization result is shown in fig. 17, and can be known from fig. 17: the main peak of the mass spectrogram can be seen to be consistent with the molecular weight of the synthesized polypeptide material, so that the synthesis of a target molecule is deduced, and the synthesis of the self-assembly material with the structure of the formula is shown to be successful.

Example 16

This example prepares a self-assembled nanoparticle solution and nanofiber dispersion of the product of example 15 by the following specific methods:

the self-assembly material prepared in example 15 was dissolved in DMSO solvent (concentration of self-assembly material was 3X 10)^-3M), 10 mu L of the solution is placed in a centrifuge tube, 990 mu L of deionized water is slowly added into the centrifuge tube to prepare a mixed solution with the water content of 98%, and the self-assembly material monomer solution (with the water content of 9%) is added8%) the obtained self-assembled nanoparticles were characterized by transmission electron microscopy, and the results are shown in fig. 18, which can be seen in fig. 18: the self-assembled material prepared in example 15 formed self-assembled particles in an aqueous solution.

Adding Her2 protein into the self-assembly nanoparticle solution obtained in the above step, wherein the concentration of Her2 protein is 3 x 10 after complete dissolution^-8And M, standing for 48 hours to obtain the nanofiber dispersion liquid. The obtained nanofibers were characterized by transmission electron microscopy, and the results are shown in fig. 19, which can be seen from fig. 19: the self-assembled polypeptide material becomes short fiber-like.

Example 17

The prepared self-assembly material is characterized by mass spectrum, and the mass spectrum characterization result is shown in fig. 20, and can be known from fig. 20: the main peak of the mass spectrogram can be seen to be consistent with the molecular weight of the synthesized polypeptide material, so that the synthesis of a target molecule is deduced, and the synthesis of the self-assembly material with the structure of the formula is shown to be successful.

Example 18

This example prepares a self-assembled nanoparticle solution and nanofiber dispersion of the product of example 17 by the following specific methods:

the self-assembly material prepared in example 17 was dissolved in DMSO solvent (concentration of self-assembly material was 3X 10)^-3M), get 10 μ L above-mentioned solution and put into the centrifuging tube, again slowly add 990 μ L deionized water into the centrifuging tube, prepare out the mixed solution of water content 98%, characterize the self-assembling nanoparticle who obtains with transmission electron microscope self-assembling material monomer solution (water content 98%), the result is as shown in figure 21, can see by figure 21: the self-assembled material prepared in example 17 formed self-assembled particles in an aqueous solution.

Adding Her2 protein into the self-assembly nanoparticle solution obtained in the above step, wherein the concentration of Her2 protein is 3 x 10 after complete dissolution^-8And M, standing for 48 hours to obtain the nanofiber dispersion liquid. The obtained nanofibers were characterized by transmission electron microscopy, and the results are shown in fig. 22, from which fig. 22 can be seen: the self-assembled polypeptide material becomes short fiber-like.

The applicant states that the invention is illustrated by the above examples to the bionic fiber network antibody self-assembly material, the preparation method and the application thereof, but the invention is not limited to the above examples, that is, the invention is not meant to be implemented only by relying on the above examples. It should be understood by those skilled in the art that any modification of the present invention, equivalent substitutions of the raw materials of the product of the present invention, addition of auxiliary components, selection of specific modes, etc., are within the scope and disclosure of the present invention.

The preferred embodiments of the present invention have been described in detail, however, the present invention is not limited to the specific details of the above embodiments, and various simple modifications may be made to the technical solution of the present invention within the technical idea of the present invention, and these simple modifications are within the protective scope of the present invention.

It should be noted that the various technical features described in the above embodiments can be combined in any suitable manner without contradiction, and the invention is not described in any way for the possible combinations in order to avoid unnecessary repetition.

SEQUENCE LISTING

<110> national center for Nano science

<120> bionic fiber network antibody self-assembly material, and preparation method and application thereof

<130> 2019

<160> 18

<170> PatentIn version 3.3

<210> 1

<211> 5

<212> PRT

<213> artificially synthesized sequence

<400> 1

Lys Leu Val Phe Phe

1 5

<210> 2

<211> 5

<212> PRT

<213> artificially synthesized sequence

<400> 2

Leu Pro Phe Phe Asp

1 5

<210> 3

<211> 5

<212> PRT

<213> artificially synthesized sequence

<400> 3

Phe Thr Ile Ser Asp

1 5

<210> 4

<211> 5

<212> PRT

<213> artificially synthesized sequence

<400> 4

Ile Thr Ser Val Val

1 5

<210> 5

<211> 5

<212> PRT

<213> artificially synthesized sequence

<400> 5

Tyr Phe Thr Glu Phe

1 5

<210> 6

<211> 5

<212> PRT

<213> artificially synthesized sequence

<400> 6

Ile Ser Asp Asn Leu

1 5

<210> 7

<211> 5

<212> PRT

<213> artificially synthesized sequence

<400> 7

Leu Asp Phe Pro Ile

1 5

<210> 8

<211> 5

<212> PRT

<213> artificially synthesized sequence

<400> 8

Phe Ala Gly Phe Thr

1 5

<210> 9

<211> 5

<212> PRT

<213> artificially synthesized sequence

<400> 9

Phe Gly Phe Asp Pro

1 5

<210> 10

<211> 5

<212> PRT

<213> artificially synthesized sequence

<400> 10

Phe Phe Val Asp Phe

1 5

<210> 11

<211> 3

<212> PRT

<213> artificially synthesized sequence

<400> 11

Asp Gly Arg

1

<210> 12

<211> 5

<212> PRT

<213> artificially synthesized sequence

<400> 12

Cys Arg Glu Lys Ala

1 5

<210> 13

<211> 6

<212> PRT

<213> artificially synthesized sequence

<400> 13

Gly Arg Gly Asp Thr Pro

1 5

<210> 14

<211> 6

<212> PRT

<213> artificially synthesized sequence

<400> 14

Cys Arg Lys Asp Lys Cys

1 5

<210> 15

<211> 12

<212> PRT

<213> artificially synthesized sequence

<400> 15

Tyr Cys Asp Gly Phe Tyr Ala Cys Tyr Met Asp Val

1 5 10

<210> 16

<211> 7

<212> PRT

<213> artificially synthesized sequence

<400> 16

Val Asn Thr Ala Asn Ser Thr

1 5

<210> 17

<211> 12

<212> PRT

<213> artificially synthesized sequence

<400> 17

Ala His Lys His Val His His Val Pro Val Arg Leu

1 5 10

<210> 18

<211> 12

<212> PRT

<213> artificially synthesized sequence

<400> 18

Cys Gly Lys Gly Gly Met Ser Arg Thr Met Ser Gly

1 5 10

Claims

1. The bionic fiber network antibody self-assembly material is characterized by comprising targeting units R which are sequentially connected through amido bonds₃Fiber unit R₂And a hydrophobic unit R₁The three units are connected through amide bonds, and the chemical structure of the three units is shown as the formula (I):

R₁-R₂-R₃formula (I);

2. The biomimetic fiber network antibody self-assembly material of claim 1, wherein R is₁The chemical structure of (a) is selected from any one of the following structures:

wherein n1, n2 and n3 are respectively and independently selected from any integer of 1-18; the dotted line represents the attachment site.

3. The biomimetic fiber network antibody self-assembly material of claim 1 or 2, wherein R is₂Any one of the following polypeptide sequences:

4. the biomimetic fiber network antibody self-assembly material of any one of claims 1-3, wherein R is₃Any one of the following polypeptide sequences:

5. the biomimetic fiber network antibody self-assembly material of any one of claims 1-4, wherein R is₁Has a chemical structure ofThe dotted line represents the attachment site, said R₂Derived from the polypeptide sequence Phe-Phe-Val-Asp-Phe, said R₃Is derived from the polypeptide sequence Asp-Gly-Arg.

6. The biomimetic fiber network antibody self-assembly material of any one of claims 1-5, wherein R is₂Derived from the polypeptide sequence Lys-Leu-Val-Phe-Phe, said R₃Derived from the polypeptide sequence Tyr-Cys-Asp-Gly-Phe-Tyr-Ala-Cys-Tyr-Met-Asp-Val, said R₁Has a chemical structure ofThe dotted line indicates the attachment site.

7. The biomimetic fiber network antibody self-assembly material of any one of claims 1-6, wherein R is₂From the polypeptide sequence Phe-Phe-Val-Asp-Phe, saidR₃Derived from the polypeptide sequence Tyr-Cys-Asp-Gly-Phe-Tyr-Ala-Cys-Tyr-Met-Asp-Val, said R₁Has a chemical structure ofThe dotted line indicates the attachment site.

8. The biomimetic fiber network antibody self-assembly material of any one of claims 1-7, wherein R is₂Derived from the polypeptide sequence Ile-Ser-Asp-Asn-Leu, said R₃From the polypeptide sequence Asp-Gly-Arg, said R₁Has a chemical structure ofThe dotted line indicates the attachment site.

9. The preparation method of the bionic fiber network antibody self-assembly material of any one of claims 1 to 8, wherein the preparation method comprises the following steps:

10. Use of the biomimetic fiber network antibody self-assembly material according to any of claims 1-9 in the preparation of a medicament for inhibiting tumor growth, metastasis or invasion.